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Abstract.  Tissue-specific interactions  with specialized 
high endothelial venules (HEV) direct the homing of 
lymphocytes from the blood into peripheral  lymph 
nodes, mucosal lymphoid organs,  and tissue sites of 
chronic  inflammation.  These interactions have been 
demonstrated in all mammalian  species examined and 
thus appear highly conserved. To assess the degree of 
evolutionary divergence in lymphocyte-HEV recogni- 
tion mechanisms,  we have studied the ability of lym- 
phocytes to interact with HEV across species barriers. 
By using an in vitro assay of lymphocyte binding to 
HEV in frozen sections of lymphoid tissues, we con- 
firm that mouse, guinea pig, and human lymphocytes 
bind to xenogeneic as well as homologous HEV.  In 
addition,  we show that mouse and human lymphoid 
cell lines that bind selectively to either peripheral 
lymph node or mucosal vessels (Peyer's patches, 
appendix) in homologous lymphoid tissues exhibit the 
same organ specificity in binding to xenogeneic HEV. 
Furthermore,  monoclonal antibodies that recognize 
lymphocyte "homing receptors" and block homologous 
lymphocyte binding to peripheral  lymph node or to 
mucosal HEV, also inhibit lymphocyte interactions 
with xenogeneic HEV in a tissue-specific fashion. 
Similarly, anti-HEV antibodies against organ-specific 
mouse high endothelial cell "addressins" involved in 
lymphocyte homing to peripheral  lymph node or mu- 
cosal lymphoid organs,  not only block the adhesion 
of mouse lymphocytes but also of human lymphocytes 
to target mouse HEV.  The results illustrate a  remark- 
able degree of functional conservation of elements 
mediating these cell-cell recognition events involved in 
organ-specific lymphocyte homing. 
M 
ANY developmentally  important  cell-cell interac- 
tions  appear highly  conserved during  evolution. 
Examples  include  neuronal  targetting  and  other 
morphogenetic cell movements during embryogenesis,  sper- 
matozoan  binding  to ova, and specific cellular  interactions 
during immune responses.  The occurrence of identical cell- 
cell interactions  in different species does not preclude,  how- 
ever, the possibility of evolutionary change in the molecular 
mechanisms  involved. In fact, comparisons of glycoprotein 
receptors (e.g., CD4, CD8; references  25, 26, 38) and en- 
zymes (e.g., cytochrome c;  14) from different species indi- 
cate  that  substantial  modifications,  including  numerous 
amino acid substitutions,  occur in most proteins during  the 
evolutionary divergence of species. That recent evolutionary 
changes have also occurred in a number of well-character- 
ized cell adhesion molecules (including neural and liver cell 
adhesion  molecules [N-CAM and L-CAM; 16], fibronectin 
receptors and  related  integrins  [19, 29],  the LFA-1/Mac-1 
family  [reviewed  in  31] and lymphocyte homing  receptors 
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[reviewed in 5]) is indicated by the existence of serologically 
defined differences in these molecules in different mamma- 
lian  species.  The evolutionary  drift  implied  could permit 
significant  divergence  in the functional  characteristics  and 
compatibility  of adhesion  molecules in differing species,  as 
well, although such divergence in functional properties is not 
necessary if evolutionary  alterations  effect only noncritical 
protein  domains. 
To assess evolutionary  change  in  functional  aspects of 
structures mediating conserved cellular interactions requires 
determination  of the degree to which  such interactions  are 
possible between cells of different species. We previously ap- 
plied this  approach  to the analysis  of a  highly  conserved 
cell-cell interaction,  the specific binding of lymphocytes to 
specialized  high endothelial  venules  (HEV) t (7).  The abil- 
ity of lymphocytes from several vertebrate species to bind to 
mouse lymph node HEV was shown to decline exponentially 
with increasing evolutionary distance of the lymphocyte do- 
nor from the mouse. The results were interpreted as suggest- 
1. Abbreviations used in this paper:  HEV, high endothelial venules; PBL, 
peripheral blood lymphocytes; PLN, peripheral lymph nodes; PP, Peyer's 
patches; RAR, relative adherence ratios. 
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lymphocyte-HEV recognition systems in diverging species, 
presumably as a result of continuous random changes in the 
interacting  lymphocyte and  endothelial  cell  surface struc- 
tures involved. 
A  corollary  of this hypothesis,  not examined  in  earlier 
studies because in vitro assays using nonmurine  HEV had 
not been developed, was that HEV from any species should 
bind homologous lymphocytes best with progressive decline 
in  the efficiency of interaction  with  evolutionary  distance 
separating  the HEV and lymphocyte donors.  We have now 
tested this prediction by assessing the interaction of mouse, 
guinea pig, and human lymphocytes with HEV in homolo- 
gous and xenogeneic combinations.  We have assessed lym- 
phocyte binding to both peripheral  lymph node (PLN) and 
to mucosal (Peyer's patch or appendix)  HEV from each of 
the species studied because lymphocytes use distinct recog- 
nition systems to interact with HEV in these different lym- 
phoid organs (9). We employed a simple in vitro assay system 
in which  lymphocytes bind to HEV in frozen  sections of 
these lymphoid tissues (8, 20, 32). In previous studies, it has 
been shown that lymphocyte binding to HEV in this frozen 
section  assay  closely  predicts  xenogeneic  or  homologous 
lymphocyte interactions with mouse HEV under more physi- 
ologic conditions  either during  perfusion  through  the sys- 
temic vasculature or in short-term  in vivo localization  ex- 
periments (6,  7). 
In contradiction of our previous hypothesis, the results in- 
dicate  that  the functional  interactions  and,  by implication 
from mAb inhibition studies, the molecular mechanisms of 
lymphocyte-HEV recognition are highly conserved among 
mammalian species, occurring with similar tissue specificity 
and antibody inhibition  characteristics  even in xenogeneic 
combinations (mouse/human) in which lymphocyte and en- 
dothelial cell donors are separated by >180 million years of 
evolution (30).  The findings imply a remarkable degree of 
conservation in the function and specificity of mechanisms 
involved in lymphocyte-endothelial cell recognition during 
the divergence of mammalian  species. 
Materials and Methods 
Cell suspensions 
Mouse and  guniea  pig lymphocytes were obtained by  pressing minced 
mesenteric lymph nodes through a 200-guage stainless steel screen, using 
cell  suspension medium  (RPMI  1640  containing 5%  FCS  and  10  mM 
Hepes, pH 7.2-7.3,  hereafter referred to as medium) to rinse. Lymphocytes 
were passed through a nylon monofilament mesh (nitex; Sullivan, Inc., San 
Francisco, CA), to produce a  single cell suspension. Human peripheral 
blood lymphocytes (PBL) from normal healthy adults (ages 20-40 yr) were 
isolated  using  FicolI-Hypaque (Histopaque-1077;  Sigma  Chemical  Co., 
St.  Louis, MO). 
Animals 
BALB/c and C3H/eb mice were purchased from the Institute for Medical 
Research (San Jose, CA) and were maintained in our colony. Hartley Albino 
Guinea pigs (EZH Caviary,  Williams, CA) were used. 
Tissues 
Human PLN and appendix were from surgical or biopsy specimens, deter- 
mined to be pathologically normal. PLNs (axillary,  brachial and cervical 
lymph nodes) and Peyer's patches (PP) of 6-wk-old BALB/c mice and of 10- 
wk-old guinea pigs were used. 
Cell Lines 
The mouse tumor cell lines used were 38C13,  a chemical carcinogen-in- 
duced C3H/eb lymphoma (3,  18);  P815,  a  chemical carcinogen-induced 
DBA/2 mastocytoma (17); and RAWll2, an Abelson virus induced BALB/c 
lymphoma (kind gift from R. Coffman, DNAX Corp., Palo Alto, CA; 27). 
Human B cell lymphoblastoid and tumor cell lines were gifts from E. Engle- 
man (KCA), the late H. Kaplan (LB25), and S. Smith (KW, a B cell lym- 
phoma cell line derived from a pediatric patient) all from Stanford Univer- 
sity School of Medicine, Stanford, CA. 
mAbs 
MEL-14 (17), a rat IgG2a; Hermes-3 (21), a mouse IgG2a; and MECA-367 
(35), a rat IgG2a; have been described. 30G12 (24), specific for the mouse 
common leukocyte antigen (gift from J. Ledbetter, Oncogen, Seattle, WA) 
was used as a rat IgG2a control for MEL-14. Mouse IgG2a control antibod- 
ies for Hermes-3 included H2/33, which defines a distinct epitope on the 
human lymphocyte Hermes antigen (21, 22) and does not block lymphocyte 
binding to HEV; and UPC 10 (purified myeloma protein, Sigma Chemical 
Co., St. Louis, MO). MECA-20 (15), a rat IgG2a anti-mouse endothelial 
cell antibody was used as a control for MECA-367.  MECA-79 (kindly pro- 
vided by P. R. Streeter), a rat IgM, is an anti-addressin antibody that inhibits 
the binding of mouse lymphocytes to peripheral node HEV in vivo and in 
vitro. The class matched control for MECA-79 was OZ-42, a rat IgM mAb 
that recognizes a determinant restricted to developing mouse brain (a gener- 
ous gift from L. B. Pickford and R. Rouse, Stanford, CA). 
In Vitro  Assay of  Lymphocyte Binding to HEV 
Preparation of frozen sections: human, mouse, and guinea pig lymphoid tis- 
sues were embedded in Tissue Tek II OCT compound (Miles Scientific, 
Naperville, IL) and frozen on dry ice. Mounted tissue was stored at -70°C 
until used. Freshly cut 10-1tm frozen sections were placed on clean glass 
microscope slides. Wax pen circles (Mark-tex, Tech Pen; and Mark-Tex 
Corp., Englewood, N J) 1.8 cm in internal diameter were drawn around the 
lymphoid tissue. To avoid the reported lymphotoxicity of OCT compound 
(4), the OCT was removed from the slides using fine forceps. Lymphocytes 
decanted from the slides after completion of the HEV assay were viable, 
as assessed by trypan blue or propidium iodide exclusion. 
In vitro HEV assay conditions: modifications of  the original Stamper and 
Woodruff assay (32)  have recently been adapted to several species (4, 20, 
34). The mouse and human in vitro HEV assays as performed by us have 
been described in detail (8, 20, 33). Briefly, sample lymphocytes in 100-gl 
medium were incubated for 30 min at 7°C with gentle agitation of freshly 
cut, frozen sections of mouse, guinea pig, or human lymphoid tissues. Lym- 
phocytes were applied at a concentration of 3  ×  107/ml,  well within the 
range in which the number of cells binding per unit area of HEV varies 
linearly with the input cell concentration (8, 20). After incubation, the cell 
suspensions were gently removed and the slides with adherent cells were 
fixed for at least  1 h at 4°C in  lax  PBS containing  1% glutaraldehyde 
(diluted from 49%  stock, EM Science, Cherry Hill, NJ). 
To adapt the assay to guinea pig lymphoid sections, we assessed the 
effects of temperature, speed of rotation, duration of incubation, and cell 
concentration on binding of guinea pig and mouse lymphocytes to guinea 
pig lymph node HEV. We found the same conditions described above to be 
optimal (data not presented). 
To facilitate quantitative comparisons between experiments, an internal 
standard population of FITC-labeled lymphocytes (10) was mixed with each 
sample population before assay. The fixed tissue sections were examined un- 
der a  microscope with darkfield illumination. Cell binding to HEV was 
counted single blind. In each experiment, a minimum of six sections for 
each sample population were examined so that >100 HEV could be counted 
per sample. Data reduction and analyses were as described (8, 20,  33). 
Results are presented as relative adherence ratios (RAR) +  standard er- 
ror (9, 20).  The RAR is the calculated number of sample cells bound to 
HEV  per  reference cell  binding  under  identical  conditions (see figure 
legends). The reference populations employed in each experiment are de- 
scribed in the figure legends. 
Antibody Inhibition of  Lymphocyte-HEV Binding 
Sample lymphocytes (either mouse or human PBL) were incubated on ice 
tor 1 h with the anti-homing receptor antibodies (MEL-14 or Hermes-3) or 
isotype-matched controls (a-T200  or H2/33) at a concentration of I00 lag/3 
x  107 cells.  The antibodies were included during  the HEV assay.  For 
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antibody-treated lymphocytes were placed in parallel on serial frozen sec- 
tions of mouse PLN,  mouse PP, human PLN,  and appendix tissue. The 
number of MEL-14-treated cells bound per HEV was determined single 
blind by microscope, and the average was divided by the average number 
of control antibody cells per HEV  (20) to yield a  PAR.  For Hermes-3 
blocking studies, a mouse FITC internal standard lymphocyte population 
was used and the PAR was calculated in the usual manner as above (9). 
In each experiment, a  control population of lymphocytes incubated with 
medium alone was also included. Results for each sample population were 
expressed as a  percent of control (untreated, medium alone) lymphocyte 
binding +  standard error. 
The anti-vascular addressin antibodies, MECA-367 and MECA-79, or 
isotype-matched controls, MECA-20 and OZ-42, respectively, were prein- 
cubated on freshly cut serial frozen tissue sections at 100 I.tg/ml for 30 min 
at 7°C. The antibodies were then gently decanted off and equal numbers of 
sample cells were added to the sections for the HEV assay. The number 
of cells binding per HEV were counted single blind under the microscope. 
Control treatments with medium alone were included in each experiment. 
Results were expressed as a percent of lymphocyte binding to control HEV. 
Results 
It has been shown that lymphocytes use functionally distinct 
and independently regulated systems to interact with HEV in 
different tissue sites, including PLN (9,  11,  17, 21), the mu- 
cosal lymphoid organs (PP or appendix; 9,  11,  17, 21, 35), 
inflamed synovium (21, 23), and perhaps other tissues. Mo- 
lecular  mechanisms  involved  in  lymphocyte  recognition 
of PLN  and  mucosal  HEV  have been  characterized and 
shown to involve gp90-kD lymphocyte surface "homing re- 
ceptors" (12,  17, 21, reviewed in 5), and tissue-specific en- 
dothelial cell antigens termed "vascular addressins" (35). 
To examine the evolutionary conservation of  the functional 
recognition events involved, we have assessed the binding of 
homologous and xenogeneic lymphocytes to both PLN and 
to mucosal HEV from mice, guinea pigs, and humans. As 
shown in Fig. 1 a, mouse lymphocytes bind significantly bet- 
ter than guinea pig or human lymphocytes to mouse HEV, 
and guinea pig lymphocytes bind slightly better than human 
PBL.  The relative binding  is  similar on PLN and on PP 
HEV. The overall results are comparable to those described 
previously in studies examining binding to mesenteric lymph 
node HEV (7), which express both peripheral lymph node 
and mucosal determinants for lymphocyte recognition (9). 
The binding of  human PBL to mouse PLN HEV is illustrated 
in Fig.  2. 
The same relative binding efficiency (mouse lymphocytes 
>  guinea pig >  human) is observed in lymphocyte interac- 
tions with guinea pig and human HEV, as well (Fig. 1, b and 
c), although the difference in binding between mouse and 
guinea pig or human lymphocytes is somewhat less than on 
mouse HEV. This similarity in relative binding, regardless 
of the HEV donor, suggests that the mechanisms mediating 
lymphocyte recognition of  both PLN and mucosal HEV have 
been conserved to a much greater extent than hypothesized 
previously. 
Binding of Organ-specific Cell Lines 
Most normal lymphocytes, however, are thought to express 
homing receptors of several specificities (17, 33, reviewed in 
5), and therefore could potentially interact with xenogeneic 
HEV via more than one receptor class. To examine the oper- 
ation of PLN vs.  mucosal HEV recognition systems sepa- 
rately, we employed well-characterized human and mouse 
a  Relative  Binding  to  Mouse  HEV 
;~  ~_  0.50 
o.oo  ~  ~  o.oo  r+-, 
M  GP  H  M  GP  H 
Lyrnphocytes  Lymphocytes 
b  Relative  Binding  to  Guinea  Pig  HEV 
~  pp 
i 
m-  0.00 /  m  0.00 
M  GP  H  M  G  °  H 
Lyrnphocytes  Lyrnphocytes 
c  Relative  Binding  to  Human  HEV 
PLN  .~  APP 
m  0.00 ~  oc  0.00 
M  CaP  H  M  ~  H 
Lymphocytes  Lymphocytes 
Figure 1. Relative binding of mouse (M), guinea pig (GP), and hu- 
man (H) lymphocytes on homologous and xenogeneic HEV. (a) 
Relative binding to mouse HEV; peripheral lymph nodes (PLN) and 
mucosal associated Peyer's patches (PP). (b) Relative binding to 
guinea pig HEV; PLN and PP. (c) Relative binding to human HEV; 
PLN and appendix (APP). Mouse lymphocytes (M) were arbitrar- 
ily chosen as the reference population, defining an RAR of  one. The 
RAR represent the calculated number of sample lymphocytes bind- 
ing to HEV per mouse lymphocyte adhering under the same condi- 
tions. The mean ± SEM is presented, based on at least five experi- 
ments (n  =  5-12).  The RAR of mouse lymphocytes is one by 
definition. 
cell lines that express unique homing receptors capable of 
binding exclusively to (homologous) PLN or mucosal HEV. 
In the mouse system, 38C13,  a B cell lymphoma, binds 
exclusively to  HEV  in  peripheral  lymph  nodes.  P815,  a 
mastocytoma, binds  preferentially to  mucosal  (PP)  HEV. 
These specificities, reported previously (2,  17),  are illus- 
trated in the top panels of Fig. 3, a and c (data from current 
experiments). As shown in Fig. 3, b and d (top),  38C13 and 
P815 cells also bind human HEV in a tissue-specific manner, 
interacting selectively with PLN and appendix HEV, respec- 
tively. Furthermore, RAW112, a mouse pre-B cell lymphoma 
that lacks functional homing receptors and does not bind to 
either PLN or PP HEV in the mouse (2,  17; see Fig.  3, a 
and c, current data), also fails to bind to human HEV (Fig. 
3, b and d). 
Parallel  results  were  obtained  with  human  cell  lines: 
LB25, a peripheral lymph node-specific B lymphoblastoid 
line; KCA, a mucosal HEV-specific B lymphoblastoid line; 
and a nonbinding B lymphoma, KW. As illustrated in Fig. 
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in a frozen section of  mouse peripheral 
lymph node.  The PBL are the round 
dark circles  lying above the plane  of 
tissue.  The outline  of the HEV is de- 
lineated  by a distinct,  poorly stained 
basement membrane.  Thionine stain. 
Bar,  50 p.m. 
3, a-d (bottom), these lines exhibit comparable tissue-spe- 
cific binding to mouse and to human HEV. Not only is the 
qualitative organ-specificity conserved in xenogeneic inter- 
actions, but the relative binding of the cell lines (vs. the PBL 
reference population) is quantitatively similar as well on hu- 
man vs. mouse HEV. These findings support a high degree 
of functional conservation in tissue-specific lymphocyte-en- 
dothelial  cell recognition systems. 
Inhibition of  Xenogeneic Interactions by mAbs against 
Lymphocyte Homing Receptors 
mAbs have been described  that interfere  with  lymphocyte 
surface molecules involved in HEV recognition (12,  17, 21, 
28).  MEL-14  recognizes  a  gp90  putative  mouse  "homing 
receptor" and blocks mouse lymphocyte binding to PLN but 
not PP HEV (17). MEL-14 also cross reacts with putative hu- 
l~gure 3. Organ  specificity of  bind- 
ing of  mouse and human cell lines 
to  homologous  and  xenogeneic 
HEV. Binding  (RAR) of the mu- 
rine cell lines,  38C13, P815, and 
RAWll2, is expressed  relative to 
control mouse lymphocytes. Bind- 
ing  of human  cell  lines  LB25, 
KCA, and KW is presented  rela- 
tive  to human PBL.  The dotted 
lines represent  the  RAR of the 
control lymphocyte population in 
each panel.  (a) Binding to mouse 
PLN HEV. (b) Human PLN HEV. 
(c) Mouse PP HEV.  (d) Human 
appendix  (APP) HEV.  The data 
represent  the  mean  4-  SEM  of 
RAR from multiple  experiments 
(n  =  4-9). 
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cyte binding to homologous and 
xenogeneic  HEV by mAbs against 
mouse  and  human  lymphocyte 
"homing receptors" Sample cells 
(mouse and human lymphocytes) 
were pre-incubated 1 h in medi- 
um containing  the indicated mAbs 
and then were submitted (with an- 
tibody) for HEV assay. No differ- 
ence in HEV binding ability was 
noted between control cells incu- 
bated with medium alone (dotted 
line) and ceils treated with iso- 
type-matched control  antibodies 
30G12  or  H2/33  and  UPCI0 
(mlgG2a) (see Fig. 4).  Data are 
expressed as the percent of con- 
trol  binding  and  represent  the 
means + SEM of  three to five ex- 
periments per antibody treatment. 
man lymphocyte homing receptors (the gp90-kD Hermes-1 
antigen) and inhibits human lymphocyte binding to human 
PLN HEV (21). mAb Hermes-3, which sees a distinct epi- 
tope on the human Hermes-1 antigen, selectively blocks hu- 
man lymphocyte binding to human mucosal HEV (21).  To 
further address the conservation of tissue-specific recogni- 
tion mechanisms, we asked whether these anti-lymphocyte 
homing receptor antibodies could interfere with lymphocyte 
recognition of xenogeneic as well as homologous HEV. 
As shown in Fig. 4 (top in a-d),  MEL-14 inhibits mouse 
lymphocyte binding to both mouse and human PLN HEV, 
but not to HEV in mouse PP or human appendix. Similarly, 
MEL-14 inhibits human PBL binding to both mouse and hu- 
man HEV in a tissue-specific manner (Fig. 4, a-d, bottom). 
Finally, Hermes-3 blocks human lymphocyte  binding to both 
mouse and human mucosal HEV, but not to PLN HEV of 
either species (Fig. 4, a-d, bottom).  The results suggest that 
lymphocytes use the same or similar molecular mechanisms 
in binding to homologous and xenogeneic HEV. 
Inhibition with Antibodies against Vascular Addressins 
Recently, mAbs have been produced defining "vascular ad- 
dressins; tissue-specific HEV antigens involved in lympho- 
cyte-HEV binding, mAb MECA-367 defines an antigen se- 
lectively expressed by mouse mucosal HEV, blocks mouse 
lymphocyte binding to such HEV in vitro, and inhibits lym- 
phocyte homing to Peyer's patches in vivo (35).  Antibody 
MECA-79 defines a PLN node addressin, and blocks mouse 
lymphocyte interactions with homologous peripheral lymph 
node HEV in vitro and in vivo (36). 
As illustrated in Fig. 5, MECA-367 and MECA-79 also in- 
hibit the interaction of human lymphocytes with mouse mu- 
cosal and PLN HEV, and they do so in a tissue-specific man- 
ner. Thus mouse PLN and mucosal HEV appear to use the 
same mechanisms to bind homologous and xenogeneic lym- 
phocytes. Together with inhibition of  xenogeneic interactions 
by antihoming receptor antibodies, the results indicate that 
comparable mechanisms  are  involved in  homologous and 
xenogeneic lymphocyte-HEV binding, and support the con- 
servation of functional properties of lymphocyte-HEV inter- 
action molecules during mammalian evolution. 
Discussion 
Guinea pigs diverged from mice roughly 40-50 million years 
ago (30,  37).  These rodents diverged from the primate lin- 
eage ~90 million years ago (during the primary mammalian 
radiation that led to the differentiation of the various orders 
of mammals), and are therefore separated from humans by 
180 million years of evolution (30,  37).  The ability of lym- 
phocytes and HEV from these species to interact efficiently 
and specifically implies a striking conservation in functional 
lymphocyte-HEV recognition mechanisms. Additional sup- 
port for such conservation comes from the recent observa- 
tions of Stoolman et al. (34) demonstrating that mannose-6- 
phosphate and a phosphomannan from Hansenula holstii can 
inhibit lymphocyte recognition of PLN HEV in both humans 
and rats. While our quantitative data does not preclude slight 
functional divergence in the lymphocyte homing receptors 
and/or endothelial cell addressins involved, the preservation 
of organ-specific endothelial cell discrimination, even across 
rather distant species barriers (mouse vs.  human), suggests 
that such functional drift has been minimal during the evo- 
lutionary expansion of mammalian  species.  Perhaps these 
mechanisms,  which regulate the entry of lymphocyte and 
other  leukocyte subsets  into  diverse  tissues  in  the  body, 
evolved to much their present form well before mammalian 
speciation. It would be of interest to seek such tissue-specific 
endothelial cell recognition systems in avian, reptilian, and 
even more distant species. 
The present studies do not address why there are substan- 
tial  differences, as  reported previously (7),  in the overall 
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on the HEV binding of mouse and human lymphocytes. (a) Binding 
to mouse PLN HEV. (b) Mouse PP HEV. MECA-367 inhibits the 
binding of both mouse lymphocytes (top sections) and human PBL 
(bottom sections)  to mouse Peyer's patch (PP) HEV. MECA-79 
blocks the  interaction of mouse  and  human  lymphocytes with 
mouse peripheral lymph node (PLN) HEV. Isotype-matched anti- 
bodies had no effect relative to medium control sections (dotted 
line).  Results are expressed as the percent of lymphocyte binding 
on control tissue sections treated with medium alone. Data repre- 
sent the mean +  SEM of at least three experiments (n =  3-6) per 
antibody treatment. 
HEV-binding abilities of lymphocytes from different species; 
i.e., who do normal mouse lymphocytes bind better to any 
HEV than guinea pig or human lymphocytes? Such species 
differences in lymphocytes are consistent in multiple experi- 
ments, have been seen here on HEV from several donors and 
species, are displayed by mature lymphocytes regardless of 
their organ source (spleen, blood, lymph nodes; 7), and are 
observed even in short-term in vivo homing or perfusion ex- 
periments (6, 7). These species distinctions may be due to 
differences in the functional levels of homing receptors or of 
accessory adhesion  molecules expressed by lymphocytes, 
possibly reflecting an inherent difference in the physiologic 
requirement for high efficiency lymphocyte binding in the 
different species. One hypothesis is that such differences re- 
late to the size and hence to metabolism/blood circulation 
dynamics of the donating species. 
Our quantitative analyses have focussed on comparing the 
ability of lymphocytes from different species to bind to HEV: 
binding is always normalized to that of a standard lympho- 
cyte population assayed on the same or serial tissue sections. 
This approach eliminates variability due to local or individ- 
ual differences in HEV, which can be substantial. HEV from 
different individuals and even from different lymph nodes or 
regions of lymph nodes from a  given individual can vary 
greatly in their binding of lymphocytes (20). Therefore, we 
have restricted ourselves here to comparisons of the tissue 
specificity of lymphocyte binding by HEV. 
From a practical perspective, the current findings of con- 
served specificity indicate that HEV from mice can be em- 
ployed as a convenient substrate for in vitro analyses of the 
endothelial cell binding characteristics of circulating lym- 
phocytes from diverse species. It remains possible, however, 
that other leukocyte-endothelial cell interactions may not be 
as highly preserved as the tissue-specific lymphocyte-HEV 
recognition studied here;  therefore, syngeneic or homolo- 
gous combinations will always be preferred to confirm analy- 
ses involving novel leukocyte or endothelial cell systems. 
Few other cellular recognition events have been studied in 
quantitative assays of xenogeneic cell-cell interactions. It is 
noteworthy, however, that aggregation of brain  membrane 
vesicles mediated by the homophilic neural  cell adhesion 
molecule,  N-CAM,  also  occurs efficiently across  species 
barriers,  and retains its  inherent tissue-specificity in xeno- 
geneic as in homologous interactions (16).  Thus the func- 
tional properties and  specificity of N-CAM,  like those of 
lymphocyte homing receptors and vascular addressins,  ap- 
pear highly conserved even though there are significant dif- 
ferences in the antlgenicity and primary sequence of N-CAMs 
in different species (1, 13). A high degree of functional stabil- 
ity in spite of significant evolutionary change in structural 
features may be common for molecules mediating cellular 
interactions critical  for morphogenesis and  cellular posi- 
tioning. 
In conclusion, the present studies demonstrate remarkable 
conservation in the specificity and function of molecules me- 
diating tissue-specific cell-cell interactions involved in lym- 
phocyte homing in mammals. The ability of lymphocytes to 
interact with precise specificity with tissue-specific endothe- 
lial cell determinants from relatively distaMt species implies 
that there has been little functional alteration in the recogni- 
tion elements involved over at least 180 million years of evo- 
lution and suggests that these recognition systems antedate 
mammalian speciation. 
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